Search Results - "Method, Michael W"

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma by Rose, Peter G., Java, James J., Salani, Ritu, Geller, Melissa A., Secord, Angeles Alvarez, Tewari, Krishnansu S., Bender, David P., Mutch, David G., Friedlander, Michael L., Van Le, Linda, Method, Michael W., Hamilton, Chad A., Lee, Roger B., Wenham, Robert M., Guntupalli, Saketh R., Markman, Maurie, Muggia, Franco M., Armstrong, Deborah K., Bookman, Michael A., Burger, Robert A., Copeland, Larry J.

“…OBJECTIVE:To analyze clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian–peritoneal–tubal carcinoma and to develop…”
Get full text

Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study by Grushko, Tatyana A., Filiaci, Virginia L., Montag, Anthony G., Apushkin, Marsha, Gomez, Maria J., Monovich, Laura, Ramirez, Nilsa C., Schwab, Carlton, Kesterson, Joshua P., Seward, Shelly M., Method, Michael W., Olopade, Olufunmilayo I., Fleming, Gini F., Birrer, Michael J.

“…We performed a pilot study in anticipation of using long-aged precut formalin-fixed paraffin-embedded tissue sections stored in real-world conditions for…”
Get full text

Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study by Berek, Jonathan S, Edwards, Robert P, Parker, Lynn P, DeMars, Leslie R, Herzog, Thomas J, Lentz, Samuel S, Morris, Robert T, Akerley, Wallace L, Holloway, Robert W, Method, Michael W, Plaxe, Steven C, Walker, Joan L, Friccius-Quecke, Hilke, Krasner, Carolyn N

“…The aim of this study was to investigate the efficacy and safety of intraperitoneal catumaxomab in heavily pretreated patients with chemotherapy-refractory…”
Get more information

Patient–provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer by Donovan, Heidi Scharf, Hartenbach, Ellen M., Method, Michael W.

“…Optimal cancer symptom management requires effective patient–health care provider (HCP) communication. The goals of this study were to 1) describe symptom…”
Get full text

Creation and Implementation of an Environmental Scan to Assess Cancer Genetics Services at Three Oncology Care Settings by Bednar, Erica M., Walsh, Michael T., Baker, Ellen, Muse, Kimberly I., Oakley, Holly D., Krukenberg, Rebekah C., Dresbold, Cara S., Jenkinson, Sandra B., Eppolito, Amanda L., Teed, Kelly B., Klein, Molly H., Morman, Nichole A., Bowdish, Elizabeth C., Russ, Pauline, Wise, Emaline E., Cooper, Julia N., Method, Michael W., Henson, John W., Grainger, Andrew V., Arun, Banu K., Lu, Karen H.

“…An environmental scan (ES) is an efficient mixed-methods approach to collect and interpret relevant data for strategic planning and project design. To date,…”
Get full text

Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer by Hess, Lisa M, Stehman, Frederick B, Method, Michael W, Weathers, Tess D, Gupta, Paridha, Schilder, Jeanne M

“…Abstract Objectives There is a lack of knowledge about the health care events experienced by individual patients that lead to a definitive diagnosis of ovarian…”
Get full text

Abstract P5-08-18: Mortality rates associated with clinical and pathological characteristics of hormone receptor positive human epidermal growth factor receptor 2 negative early breast cancer: An analysis of the 2010-2016 surveillance, epidemiology, and end results data by Brown, Jacqueline, Method, Michael W, Nelson, David R

“…Background: Breast cancer in the United States is diagnosed in over 90% of cases prior to evidence of distant metastasis (stages I–III) with approximately 70%…”
Get full text

Characterization of long-term survivors from four clinical trials examining patients with folate receptor alpha–positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine by O'Malley, David M., Lorusso, Domenica, Oaknin, Ana, Van Gorp, Toon, Banerjee, Susana N., González-Martín, Antonio, Murphy, Conleth G., de Gregorio, Nikolaus, Konecny, Gottfried E., Method, Michael W., Wang, Yuemei, Coleman, Robert L., Matulonis, Ursula A., Moore, Kathleen N., Colombo, Nicoletta

“…5582 Background: Mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting folate receptor-alpha (FRα), is the first novel treatment to…”
Get full text

Recurrence risk in early breast cancer as defined by clinicopathologic features by Sheffield, Kristin M., Peachey, Jessica R., Method, Michael W., Grimes, Brenda R., Brown, Jacqueline, Saverno, Kim R., Zhu, Yajun Emily, Lee, Kimberley T

“…Abstract only e18581 Background: While most patients (pts) with HR+, HER2- early breast cancer (EBC) do not experience disease recurrence, those with high risk…”
Get full text

Hydropic degenerating leiomyoma presenting as pseudo-Meigs syndrome with elevated CA 125 by Dunn, James S., Anderson, Cameron D., Method, Michael W., Brost, Brian C.

“…Background: Leiomyomas rarely cause pseudo-Meigs syndrome. Increased levels of CA 125 often are associated with some types of malignancy. No reported case of…”
Get full text

A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy by Trillsch, Fabian, Schochter, Fabienne, Park-Simon, Tjoung-Won, Reuss, Alexander, Fehm, Tanja N., Wimberger, Pauline, Bronger, Holger, Schmalfeldt, Barbara, Sehouli, Jalid, Marmé, Frederik, Heitz, Florian, Mahner, Sven, Fredrich, Michaela, Barth, Stefanie, Stec, James Joseph, Method, Michael W., Harter, Philipp

“…TPS5618 Background: Despite radical primary surgery and carboplatin/paclitaxel-based chemotherapy in combination with anti-angiogenic bevacizumab and/or PARP…”
Get full text

Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study by Matulonis, Ursula A., Oaknin, Ana, Pignata, Sandro, denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A., Romeo, Marga, Harter, Philipp, Murphy, Conleth G., Wang, Jiuzhou, Method, Michael W., Esteves, Brooke, Coleman, Robert L., Lorusso, Domenica

“…5512 Background: SORAYA is a global single arm phase 3 study evaluating MIRV in patients (pts) with FRα high platinum-resistant ovarian cancer (PROC). MIRV is…”
Get full text

Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials by Moore, Kathleen N., Lorusso, Domenica, Oaknin, Ana, Oza, Amit M., Colombo, Nicoletta, Van Gorp, Toon, O'Malley, David M., Banerjee, Susana N., Murphy, Conleth G., Harter, Philipp, Konecny, Gottfried E., Pautier, Patricia, Method, Michael W., Wang, Jiuzhou, Birrer, Michael J., Coleman, Robert L., Matulonis, Ursula A.

“…5574 Background: Available chemotherapies for platinum-resistant ovarian cancer (PROC) have limited clinical activity and considerable toxicity. Mirvetuximab…”
Get full text

Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study by Grushko, Tatyana A., Filiaci, Virginia L., Montag, Anthony G., Apushkin, Marsha, Gomez, Maria J., Monovich, Laura, Ramirez, Nilsa C., Schwab, Carlton, Kesterson, Joshua P., Seward, Shelly M., Method, Michael W., Olopade, Olufunmilayo I., Fleming, Gini F., Birrer, Michael J.

“…We performed a pilot study in anticipation of using long-aged precut formalin-fixed paraffin-embedded tissue sections stored in real-world conditions for…”
Get full text

A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer by Becerra, Carlos, Garcia, Agustin A., Hays, John L., Method, Michael W., Richey, Stephen Lane, Langleben, Adrian, Richards, Donald A., Cote, Gregory Michael, Kossler, Kimiko, Li, Wei, Li, Youzhi, Hitron, Matthew, Li, Chiang

“…Abstract only 5548 Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription…”
Get full text

A randomized phase II study assessing an optimized schedule of oregovomab (O) anti-CA125 vaccination with carboplatin paclitaxel (CP) relative to CP alone in front-line treatment of optimally cytoreduced stage III/IV ovarian cancer (EOC) by Ferrandina, Gabriella, Braly, Patricia S., Terranova, Corrado, Salutari, Vanda, Ricci, Caterina, Raspagliesi, Francesco, Lorusso, Domenica, Panici, Pierluigi Benedetti, Scollo, Paolo, Plotti, Francesco, Brewer, Molly, Method, Michael W., Holloway, Robert W., Madiyalakan, Madi, Nicodemus, Christopher F., Pecorelli, Sergio L., Scambia, Giovanni, Angioli, Roberto

“…Abstract only 5536 Background: In a phase II study of vaccination schedule in front-line combinatorial treatment of EOC (Braly JIT 2009), simultaneous day…”
Get full text

Dissemination of universal genetic testing to three unique oncology care settings by Bednar, Erica, Muse, Kimberly I., Oakley, Holly D., Baker, Ellen, Walsh, Michael T., Krukenberg, Rebekah C., Dresbold, Cara S., Morman, Nichole A., Bowdish, Elizabeth C., Cooper, Julia N., Wise, Emaline E, Eppolito, Amanda L., Teed, Kelly B., Klein, Molly H., Chao, Han, Method, Michael W., Grainger, Andrew V., Henson, John W., Lu, Karen H.

“…Abstract only 1590 Background: Efforts are occurring across the United States to improve the rates of identification and standard of care genetic counseling…”
Get full text

The Role of Radioimmunoscintigraphy and Computed Tomography Scan Prior to Reassessment Laparotomy of Patients with Ovarian Carcinoma: A Preliminary Report by Method, Michael W, Serafini, Aldo N, Averette, Hervy E, Rodriguez, Michael, Penalver, Manuel A, Sevin, Bernd-Uwe

Get full text

Efficacy of radical hysterectomy as treatment for patients with small cell carcinoma of the cervix by Sevin, Bernd‐Uwe, Method, Michael W., Nadji, Mehrdad, Lu, Ying, Averette, Hervy A.

“…BACKGROUND This study was performed to identify pathologic and clinical features that best predict disease free survival of patients with early stage small…”
Get full text

Management of cervical cancer in pregnancy by Method, Michael W., Brost, Brian C.

“…Carcinoma of the cervix is the most common gynecologic cancer found during pregnancy. Management and treatment of this condition depend on cancer stage,…”
Get full text